Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Operating Leases (2019 - 2025)

Protalix BioTherapeutics (PLX) has 7 years of Operating Leases data on record, last reported at $6.8 million in Q3 2025.

  • For Q3 2025, Operating Leases rose 62.36% year-over-year to $6.8 million; the TTM value through Sep 2025 reached $6.8 million, up 62.36%, while the annual FY2024 figure was $4.0 million, 12.88% down from the prior year.
  • Operating Leases reached $6.8 million in Q3 2025 per PLX's latest filing, up from $3.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $6.8 million in Q3 2025 and bottomed at $3.8 million in Q1 2025.
  • Average Operating Leases over 5 years is $4.4 million, with a median of $4.3 million recorded in 2024.
  • The widest YoY moves for Operating Leases: up 62.36% in 2025, down 15.29% in 2025.
  • A 5-year view of Operating Leases shows it stood at $4.4 million in 2021, then dropped by 4.73% to $4.2 million in 2022, then rose by 10.84% to $4.6 million in 2023, then dropped by 12.88% to $4.0 million in 2024, then skyrocketed by 68.41% to $6.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $6.8 million in Q3 2025, $3.9 million in Q2 2025, and $3.8 million in Q1 2025.